Oral chemo option to be considered for AML in Europe

22 August 2022
otsuka-big

The European medicines regulator has started reviewing a submission from Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) for its acute myeloid leukemia (AML) therapy ASTX727.

Developed by its subsidiary Astex Pharmaceuticals, Otsuka is seeking approval to market the oral fixed-dose combination of decitabine and cedazuridine as an option for AML in the first-line setting.

The current standard of care for AML is hospital-administered intravenous chemotherapy infusions, or for those who are not eligible, parenterally administered hypomethylating agents.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical